The impact of risperidone in hospitalization of schizophrenic patients: A retrospective study in three Brazilian cities;Impacto do uso da risperidona na hospitalizacao de pacientes esquizofrenicos: Estudo retrospectivo em tres cidades brasileiras

Jornal Brasileiro de Psiquiatria

Volumn 48, Issue 10, 1999, Pages 461-464

  De Lima, Maurícìo Silva ^a   De Jesus Mari, Jair ^a   Trefiglio, Roberta Pereira ^a   Bacaltchuk, Josué ^a  

^a NONE

Author keywords

Antispychotics; Cost effectiveness; Neuroleptics; Risperidone; Schizophrenia

Indexed keywords

ANTIPARKINSON AGENT; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ARTICLE; BRAZIL; CLINICAL ARTICLE; COST BENEFIT ANALYSIS; FEMALE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MALE; MENTAL HEALTH SERVICE; SCHIZOIDISM; SCHIZOPHRENIA;

EID: 0032700030     PISSN: 00472085     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Albright PS, Livingstone S, Keegan DL, et al. Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: a retrospective analysis using the Saskatchewan Health Linkable Databases. Clin Drug Invest 1996;11:289-2199.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Washington: American Psychiatric Press; 1994.
3. Bandolfi G, Dufour H, Patris M et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry 1998;155:499-504
4. Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta analysis. Int Clin Psychopharmacol 1995;10:207-213.
5. Carter C, Stevens M, Durkin M. Effects of risperidone therapy on the use of mental health care resources in Salt Lake County, Utah. Clin Ther 1998;20(2):352-363.
6. Cookson RF, Huybrechts KF. Risperidone: An assessment of its economics benefits in the treatment of schizophrenia. J Med Econ 1998;1:103-134.
7. Daniels BA, Kirkby KC, Hay DA et al. Predictability of rehospitalisation over 5 years for schizophrenia, bipolar disorder and depression. Aust N Z J Psychiatry 1998;32:281-286.
8. Davies A, Langley PC, Keks NA et al. Risperidone versus haloperidol: II. Cost-effectiveness. Clin Ther 1998;20:196-213.
9. Davies LM, Drummond MF. Economies and schizophrenia: the real cost. Br J Psychiatry 1994;165 (Suppl. 25):18-21.
10. Finley PR, Sommer BR, Corbitt JL et al. Risperidone: clinical outcome predictors and cost-effectiveness in a naturalistic setting. Psychopharmacol Bull 1998;34(1):75-81.
11. Foster GM, Marshall Jr BD, Wirshing WC et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997;154:799-804.
12. Foster RH, Goa KL. Risperidone: A pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 1998;14:97-133.
13. Frankenburg FR, Hegarty JD. Cost considerations in the treatment of schizophrenia. CNS Drugs 1996;5:75-82.
14. Huybrechts K. Outcomes assessment is schizophrenia: methodological issues. Schizophr Rev 1996;4 (Suppl. 3):2-3.
15. Kasper S. Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia. Int Clin Psychopharmacol 1998;13:253-262.
16. Kleiser E, Lehmann E, Kinzler E et al. Randomized double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 1995;15:45S-51S.
17. Knapp M, Kavanagh S. Economic outcomes and costs in the treatment of schizophrenia. Clin Ther 1997;19:128-138.
18. Konrad C, Schormair C, Knickelbein U et al. Risperidone and clozapine in pharmaco-resistant schizophrenia. Pharmacopsychiatry 1997;30:190.
19. Lemmens P, Brecher M, Van Baelen B. A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr Scand 1999;97:1-11.
20. Lindström E, Eriksson B, Hellgren A et al. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995;17:402-412.
21. Lindström E. The hidden cost of schizophrenia. J Drug Dev Clin Pract 1996;7:281-288.
22. Marcolin MA. Escala de qualidade de vida em pacientes esquizofrênicos. Rev Psiq Clin 1998;25:352-356.
23. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835.
24. Procyshyn R, Zerjav S. Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone and olanzapine. Clin Ther 1998;20:1203-17.
25. Song F. Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. J Clin Psychopharmacol 1997;11:65-71.
26. Stip E, Lussier I. The effect of risperidone on cognition in patients with schizophrenia. Can J. Psychiatry 1996;41(Suppl. 2): 35-40.
27. Viale G, Mechling L, Maislin G et al. Impact of risperidone on the use of mental health care resources. Psychiatr Serv 1997;48:1153-1159.